Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1.
Kasumi-1
acute myeloid leukemia
bortezomib
decitabine
Journal
Experimental and therapeutic medicine
ISSN: 1792-0981
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
20
01
2020
accepted:
17
11
2020
entrez:
25
1
2021
pubmed:
26
1
2021
medline:
26
1
2021
Statut:
ppublish
Résumé
In the present study, the ability of the proteasome inhibitor bortezomib (BZ), an oxidative stress-inducing agent, to sensitize acute myeloid leukemia (AML) cells to decitabine (Dacogen
Identifiants
pubmed: 33488804
doi: 10.3892/etm.2021.9628
pii: ETM-0-0-09628
pmc: PMC7812574
doi:
Types de publication
Journal Article
Langues
eng
Pagination
195Informations de copyright
Copyright: © Mpakou et al.
Références
Leuk Lymphoma. 2017 Sep;58(9):1-7
pubmed: 28278716
J Immunol Res. 2017;2017:4302320
pubmed: 29124072
Blood. 2011 Sep 8;118(10):2849-56
pubmed: 21765021
Cancer. 2008 Jun;112(11):2341-51
pubmed: 18398832
J Clin Oncol. 2011 Feb 10;29(5):487-94
pubmed: 21220605
Nat Med. 1997 Jul;3(7):730-7
pubmed: 9212098
Exp Hematol. 2013 Feb;41(2):189-97
pubmed: 23085465
In Vivo. 2016 09-10;30(5):645-50
pubmed: 27566085
Leuk Lymphoma. 2013 Sep;54(9):2003-7
pubmed: 23270581
Leuk Res. 2010 Mar;34(3):364-72
pubmed: 19732952
Oncotarget. 2013 Oct;4(10):1729-36
pubmed: 24077826
Mol Med Rep. 2016 Oct;14(4):3469-75
pubmed: 27571872
Crit Rev Oncol Hematol. 2007 Feb;61(2):140-52
pubmed: 17023173
Curr Treat Options Oncol. 2017 Mar;18(3):17
pubmed: 28286924
Saudi J Biol Sci. 2018 Feb;25(2):242-247
pubmed: 29472772
Clin Cancer Res. 2004 May 15;10(10):3371-6
pubmed: 15161691
Blood. 2012 Jun 21;119(25):6025-31
pubmed: 22566605
Cancer Chemother Rep. 1973 Nov-Dec;57(4):485-8
pubmed: 4586956
Biol Pharm Bull. 2009 Jun;32(6):1105-8
pubmed: 19483324
Mol Cancer Ther. 2008 Sep;7(9):2998-3005
pubmed: 18790780
J Clin Oncol. 2011 Feb 10;29(5):591-9
pubmed: 21220598
Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8
pubmed: 20368434
Mol Cell Biol. 2004 Nov;24(22):9695-704
pubmed: 15509775
Blood. 2008 Feb 15;111(4):2364-73
pubmed: 18083845
N Engl J Med. 2016 Nov 24;375(21):2023-2036
pubmed: 27959731
Clin Cancer Res. 2008 Mar 1;14(5):1446-54
pubmed: 18316568
Leuk Res. 2015 Feb;39(2):183-91
pubmed: 25577399
Blood Adv. 2018 Dec 26;2(24):3608-3617
pubmed: 30567725
Crit Rev Oncol Hematol. 2017 Feb;110:20-34
pubmed: 28109402
Oncol Res. 2019 Jun 21;27(6):729-737
pubmed: 30837032
Int J Hematol. 2007 Nov;86(4):306-14
pubmed: 18055336
Cancer Cell. 2010 Apr 13;17(4):333-47
pubmed: 20385359
Blood. 2007 Jan 1;109(1):52-7
pubmed: 16882708
Int J Oncol. 2012 Sep;41(3):910-8
pubmed: 22767021
Anticancer Res. 2019 Dec;39(12):6673-6684
pubmed: 31810932
Blood Cancer J. 2016 Dec 2;6(12):e503
pubmed: 27911437
Prog Mol Biol Transl Sci. 2018 Jan;153:321-341
pubmed: 29389522
Int J Mol Sci. 2019 Aug 29;20(17):
pubmed: 31470642
Nature. 1994 Feb 17;367(6464):645-8
pubmed: 7509044
Cancer Biol Ther. 2006 Jul;5(7):745-8
pubmed: 16861900
Br J Haematol. 2006 Aug;134(3):253-62
pubmed: 16787504
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Leuk Lymphoma. 2014 Jul;55(7):1533-7
pubmed: 24144313
Cancer Res. 2006 Jan 1;66(1):184-91
pubmed: 16397231
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Blood. 2013 Feb 28;121(9):1633-43
pubmed: 23297133
Hematol Oncol. 2008 Jun;26(2):73-81
pubmed: 18324639